Orthofix Medical Inc. OFIX
We take great care to ensure that the data presented and summarized in this overview for Orthofix Medical Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OFIX
View all-
Armistice Capital, LLC New York, NY3.7MShares$55.5 Million0.73% of portfolio
-
Rubric Capital Management LP New York, NY3.67MShares$55 Million1.81% of portfolio
-
Black Rock Inc. New York, NY3.29MShares$49.4 Million0.0% of portfolio
-
Engine Capital Management, LP New York, NY3.04MShares$45.5 Million9.09% of portfolio
-
Morgan Stanley New York, NY2.76MShares$41.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.01MShares$30.1 Million0.0% of portfolio
-
Paradigm Capital Management Inc1.95MShares$29.2 Million1.37% of portfolio
-
Newtyn Management, LLC New York, NY1.27MShares$19.1 Million3.98% of portfolio
-
State Street Corp Boston, MA1.07MShares$16 Million0.0% of portfolio
-
Boone Capital Management LLC Atlanta, GA975KShares$14.6 Million2.86% of portfolio
Latest Institutional Activity in OFIX
Top Purchases
Top Sells
About OFIX
Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions, as well as markets regenerative non-tissue biologic solutions derived from synthetic materials. The Global Orthopedics segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
Insider Transactions at OFIX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Apr 15
2024
|
Jorge Andres Cedron CLO |
BUY
Grant, award, or other acquisition
|
Direct |
28,648
+50.0%
|
$372,424
$13.09 P/Share
|
Apr 11
2024
|
Kimberley A. Elting President, Global Orthopedics |
SELL
Payment of exercise price or tax liability
|
Direct |
2,938
-1.25%
|
$38,194
$13.95 P/Share
|
Apr 08
2024
|
Catherine M Burzik |
SELL
Payment of exercise price or tax liability
|
Direct |
47,486
-29.63%
|
$664,804
$14.23 P/Share
|
Apr 01
2024
|
Kimberley A. Elting President, Global Orthopedics |
SELL
Payment of exercise price or tax liability
|
Direct |
2,031
-0.86%
|
$28,434
$14.06 P/Share
|
Apr 01
2024
|
Geoffrey C Gillespie CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
70
-0.17%
|
$980
$14.06 P/Share
|
Mar 15
2024
|
Geoffrey C Gillespie CAO |
BUY
Grant, award, or other acquisition
|
Direct |
3,639
+8.18%
|
$47,307
$13.74 P/Share
|
Feb 01
2024
|
Kimberley A. Elting President, Global Orthopedics |
SELL
Payment of exercise price or tax liability
|
Direct |
2,015
-0.84%
|
$28,210
$14.27 P/Share
|
Jan 31
2024
|
Michael Finegan |
BUY
Grant, award, or other acquisition
|
Direct |
8,350
+50.0%
|
$108,550
$13.89 P/Share
|
Jan 31
2024
|
Alan Lee Bazaar |
BUY
Grant, award, or other acquisition
|
Direct |
8,936
+50.0%
|
$116,168
$13.89 P/Share
|
Jan 31
2024
|
Charles R. Kummeth |
BUY
Grant, award, or other acquisition
|
Direct |
8,350
+26.34%
|
$108,550
$13.89 P/Share
|
Jan 15
2024
|
Julie Andrews CFO |
BUY
Grant, award, or other acquisition
|
Direct |
32,967
+50.0%
|
$428,571
$13.65 P/Share
|
Jan 08
2024
|
Massimo Calafiore President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
141,084
+50.0%
|
$1,834,092
$13.29 P/Share
|
Jan 08
2024
|
Kevin J. Kenny President of Global Spine |
SELL
Payment of exercise price or tax liability
|
Direct |
1,511
-1.03%
|
$19,643
$13.29 P/Share
|
Jan 08
2024
|
Kevin J. Kenny President of Global Spine |
BUY
Exercise of conversion of derivative security
|
Direct |
5,959
+3.89%
|
-
|
Jan 08
2024
|
Geoffrey C Gillespie CAO |
BUY
Grant, award, or other acquisition
|
Direct |
4,703
+11.17%
|
$61,139
$13.29 P/Share
|
Jan 08
2024
|
Kimberley A. Elting President, Global Orthopedics |
SELL
Grant, award, or other acquisition
|
Direct |
18,811
-7.3%
|
$244,543
$13.29 P/Share
|
Jan 05
2024
|
Kevin J. Kenny President of Global Spine |
SELL
Payment of exercise price or tax liability
|
Direct |
2,955
-2.05%
|
$35,460
$12.67 P/Share
|
Jan 05
2024
|
Geoffrey C Gillespie CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
459
-1.39%
|
$5,508
$12.67 P/Share
|
Jan 05
2024
|
Kimberley A. Elting President, Global Orthopedics |
SELL
Payment of exercise price or tax liability
|
Direct |
5,228
-2.32%
|
$62,736
$12.67 P/Share
|
Jan 03
2024
|
Kimberley A. Elting President, Global Orthopedics |
SELL
Payment of exercise price or tax liability
|
Direct |
1,778
-0.78%
|
$21,336
$12.96 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 483K shares |
---|---|
Open market or private purchase | 7.5K shares |
Exercise of conversion of derivative security | 5.96K shares |
Payment of exercise price or tax liability | 67.1K shares |
---|---|
Grant, award, or other acquisition | 18.8K shares |
Sale (or disposition) back to the issuer | 8.94K shares |
Open market or private sale | 8.24K shares |